The reiteration of an Outperform rating and a high price target by a reputable analyst like Brian Abrahams from RBC Capital is likely to instill confidence among investors and could positively influence Biogen's stock price in the short term. The specific mention of a $364 price target suggests a strong bullish outlook on the stock, which could lead to increased investor interest and potentially drive the stock price up.